Correlation Between GeneReach Biotechnology and EirGenix

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both GeneReach Biotechnology and EirGenix at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining GeneReach Biotechnology and EirGenix into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between GeneReach Biotechnology and EirGenix, you can compare the effects of market volatilities on GeneReach Biotechnology and EirGenix and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in GeneReach Biotechnology with a short position of EirGenix. Check out your portfolio center. Please also check ongoing floating volatility patterns of GeneReach Biotechnology and EirGenix.

Diversification Opportunities for GeneReach Biotechnology and EirGenix

-0.45
  Correlation Coefficient

Very good diversification

The 3 months correlation between GeneReach and EirGenix is -0.45. Overlapping area represents the amount of risk that can be diversified away by holding GeneReach Biotechnology and EirGenix in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on EirGenix and GeneReach Biotechnology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on GeneReach Biotechnology are associated (or correlated) with EirGenix. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of EirGenix has no effect on the direction of GeneReach Biotechnology i.e., GeneReach Biotechnology and EirGenix go up and down completely randomly.

Pair Corralation between GeneReach Biotechnology and EirGenix

Assuming the 90 days trading horizon GeneReach Biotechnology is expected to under-perform the EirGenix. But the stock apears to be less risky and, when comparing its historical volatility, GeneReach Biotechnology is 1.34 times less risky than EirGenix. The stock trades about -0.1 of its potential returns per unit of risk. The EirGenix is currently generating about -0.01 of returns per unit of risk over similar time horizon. If you would invest  9,160  in EirGenix on August 30, 2024 and sell it today you would lose (50.00) from holding EirGenix or give up 0.55% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

GeneReach Biotechnology  vs.  EirGenix

 Performance 
       Timeline  
GeneReach Biotechnology 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days GeneReach Biotechnology has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in December 2024. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.
EirGenix 

Risk-Adjusted Performance

4 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in EirGenix are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal basic indicators, EirGenix may actually be approaching a critical reversion point that can send shares even higher in December 2024.

GeneReach Biotechnology and EirGenix Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with GeneReach Biotechnology and EirGenix

The main advantage of trading using opposite GeneReach Biotechnology and EirGenix positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if GeneReach Biotechnology position performs unexpectedly, EirGenix can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in EirGenix will offset losses from the drop in EirGenix's long position.
The idea behind GeneReach Biotechnology and EirGenix pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

Other Complementary Tools

Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device